CKD-512
/ Chong Kun Dang
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 16, 2025
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical
Monotherapy • New P1 trial • Solid Tumor
1 to 1
Of
1
Go to page
1